YB-1 could modulate the reactivity of tumor cells to tamoxifen and fulvestrant by affecting the estrogen receptor (ER)-human EGFR2 signaling pathway in ER-positive breast cancer cells [31]. The gene discussed is ESR1; the disease is breast cancer.